(Worthy News) – On Wednesday of this week, Israel’s Health Ministry announced that the Regeneron monoclonal antibody blend would henceforth be offered to COVID-19 patients considered at high risk of progressing to serious illness.
Regeneron is a combination of two substances, casirivimab and imdevimab, that have been found to be significantly effective in preventing mild cases of coronavirus from progressing to serious illness and death. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens. Casirivimab and imdevimab are specifically directed against the spike protein of COVID-19, designed to block the virus’ attachment and entry into human cells.
The drugs’ effectiveness in combination were confirmed as early as November of 2020 by the FDA, which granted emergency use authorization (EUA) for the treatment of mild to moderate COVID-19 for anyone over the age of 12. [ Source: Arutz Sheva (Read More…) ]